Artículos de revistas
Aspects Of Atherosclerosis And Metabolic Syndrome In Lupus Erythematosus [aspectos Da Aterosclerose E Da Síndrome Metabólica No Lúpus Eritematoso Sistêmico]
Registro en:
Acta Reumatologica Portuguesa. , v. 35, n. 3, p. 294 - 300, 2010.
0303464X
2-s2.0-78650453648
Autor
Nascimento I.S.
Quaio C.R.D.A.
Sinicato N.A.
Appenzeller S.
De Carvalho J.F.
Institución
Resumen
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease affecting mainly young women. In last decades premature atherosclerosis has been identified as an important cause of mortality due to SLE related risk factors (inflammation and treatment) and metabolic syndrome (MS). MS is a group of risk factors, originating from an abnormal metabolism, with an increased risk for developing atherosclerotic cardiovascular disease. The prevalence of MS varies from 5,5-55,4% in the general population and has been observed up to 40% in SLE, associated with advanced age, low socioeconomic status, lack of exercise, use of high doses of prednisone and disease activity. Treatment should include identification and modification of these risk factors. 35 3 294 300 Bultink, I.E., Turkstra, F., Diamant, M., Dijkmans, B.A., Voskuyl, A.E., Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus (2008) Clin Exp Rheumatol, 26, pp. 32-38 Manzi, S., Meilahn, E.N., Rairie, J.E., Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study (1997) Am J Epidemiol, 145, pp. 408-415 Urowitz, M.B., Bookman, A.A., Koehler, B.E., Gordon, D.A., Smythe, H.A., Ogryzlo, M.A., The bimodal mortality pattern of systemic lupus erythematosus (1976) Am J Med, 60, pp. 221-225 Aranow, C., Ginzler, E.M., Epidemiology of cardiovascular disease in systemic lupus erythematosus (2000) Lupus, 9, pp. 166-169 Petri, M., Perez-Gutthann, S., Spence, D., Hochberg, M.C., Risk factors for coronary artery disease in patients with systemic lupus erythematosus (1992) Am J Med, 93, pp. 513-519 Manzi, S., Systemic lupus erythematosus: A model for atherogenesis? (2000) Rheumatology (Oxford), 39, pp. 353-359 Ross, R., The pathogenesis of atherosclerosis: A perspective for the 1990s (1993) Nature, 362, pp. 801-809 Negrón, A., Molina, M., Mayor, A., Rodríguez, V., Vilá, L., Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico (2008) Lupus, 17, pp. 348-354 Zonana-Nacach, A., Santana-Sahagún, E., Jiménez-Balderas, F.J., Camargo-Coronel, A., Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus (2008) J Clin Rheumatol, 14, pp. 74-77 Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men (1997) N Engl J Med., 336, pp. 973-979. , Erratum, N Engl J Med 1997;337:356 Stary, H.C., Chandler, A.B., Glagov, S., A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association (1994) Circulation, 89, pp. 2462-2478 Napoli, C., D'Armiento, F.P., Mancini, F.P., Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions (1997) J Clin Invest, 100, pp. 2680-2690 Ridker, P.M., Buring, J.E., Shih, J., Matias, M., Hennekens, C.H., Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women (1998) Circulation, 98, pp. 731-733 Ridker, P.M., Hennekens, C.H., Roitman-Johnson, B., Stampfer, M.J., Allen, J., Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men (1998) Lancet, 351, pp. 88-92 Schönbeck, U., Varo, N., Libby, P., Buring, J., Ridker, P.M., Soluble CD40L and cardiovascular risk in women (2001) Circulation, 104, pp. 2266-2268 Wysocki, J., Skoczynski, S., Strozik, A., Hochul, B., Zygula, M., Metabolic or immunometabolic syndrome? (2005) Wiad Lek, 58, pp. 124-127 Wisse, B.E., The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity (2004) J Am Soc Nephrol, 15, pp. 792-800 Duncan, B.B., Schmidt, M.I., Chronic activation of the innate immune system may underlie the metabolic syndrome (2001) Sao Paulo Med J, 119, pp. 122-127 Galtier-Dereure, F., Biron, C., Vies, M., Bourgeois, V., Schved, J.F., Bringer, J., Vascular complications of diabetes mellitus: What role for phospholipid-binding antibodies? (1998) Lupus, 7, pp. 469-474 Wu, R., Nityanand, S., Berglund, L., Lithell, H., Holm, G., Lefvert, A.K., Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction (1997) Arterioscler Thromb Vasc Biol, 17, pp. 3159-3163 Vaarala, O., Mänttäri, M., Manninen, V., Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men (1995) Circulation, 91, pp. 23-27 Witztum, J.L., The oxidation hypothesis of atherosclerosis (1994) Lancet, 344, pp. 793-795 Reichlin, M., Fesmire, J., Quintero-Del-Rio, A.I., Wolfson-Reichlin, M., Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus (2002) Arthritis Rheum, 46, pp. 2957-2963 De Carvalho, J.F., Borba, E.F., Viana, V.S., Bueno, C., Leon, E.P., Bonfa, E., Anti-lipoprotein lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus erythematosus? (2004) Arthritis Rheum, 50, pp. 3610-3615 Doria, A., Shoenfeld, Y., Wu, R., Risk factors for sub-clinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus (2003) Ann Rheum Dis, 62, pp. 1071-1077 Ross, R., Atherosclerosis--an inflammatory disease (1999) Engl J Med, 340, pp. 115-126 Borba, E.F., Bonfa, E., Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies (1997) Lupus, 6, pp. 533-539 Ilowite, N.T., Samuel, P., Ginzler, E., Jacobson, M.S., Dyslipoproteinemia in pediatric systemic lupus erythematosus (1988) Arthritis Rheum, 31, pp. 859-863 Bruce, I.N., Urowitz, M.B., Gladman, D.D., Hallett, D.C., Natural history of hypercholesterolemia in systemic lupus erythematosus (1999) J Rheumatol, 26, pp. 2137-2143 De Carvalho, J.F., Bonfá, E., Borba, E.F., Systemic lupus erythematosus and "lúpus dyslipoproteinemia" (2008) Autoimmun Rev, 7, pp. 246-250 Borba, E.F., Carvalho, J.F., Bonfá, E., Mechanisms of dyslipoproteinemias in systemic lupus erythematosus (2006) Clin Dev Immunol, 13, pp. 203-208 De Carvalho, J.F., Borba, J.F., Viana, V.S., Bueno, C., Leon, E.P., Bonfá, E., Anti-lipoprotein lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus erythematosus? (2004) Arthritis Rheum, 50, pp. 3610-3615 Definition, diagnosis and classification of diabetes mellitus and its complications, pp. 31-33. , WHO consultations: WHO/NCD/NCS/992 Lopes, H.F., Síndrome Metabólica: Aspectos históricos, prevalência, e morbidade e mortalidade (2004) Rev Soc Cardiol, 4, pp. 539-543 Alberti, R.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation (1998) Diabet Med, 15, pp. 539-553 Defronzo, R.A., Tobin, J.D., Andres, R., Glucose clamp technique: A method for quantifying insulin secretion and resistance (1979) Am J Physiol, 237, pp. E214-E223 Harano, Y., Ohgaku, S., Hidaka, H., Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity (1977) J Clin Endocrinol Metab, 45, pp. 1124-1127 Bergman, R.N., Ider, Y.Z., Bowden, C.R., Cobelli, C., Quantitative estimation of insulin sensitivity (1979) Am J Physiol, 236, pp. E667-E677 Caumo, A., Vicini, P., Cobelli, C., Is the minimal model too minimal? (1996) Diabetologia, 39, pp. 997-1000 Laakso, M., How good a marker is insulin level for insulin resistance? (1993) Am J Epidemiol, 137, pp. 959-965 Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man (1985) Diabetologia, 28, pp. 412-419 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001) Jama, 285, pp. 2486-2497 (2000) The Asia-Pacific Perspective, , World Health Organisation, Western Pacific Region, Redefining Obesity and its Treatment, WHO/IASO/IOTF Lean, M.E., Han, T.S., Morrison, C.E., Waist circumference as a measure for indicating need for weight management (1995) Bmj, 311, pp. 158-161 Alberti, K.G.M.M., Eckel, R.H., Scott, M., Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention National Heart, Lung, and Blood Institute American Heart Association World Heart Federation International Atherosclerosis Society and International Association for the Study of Obesity (2009) Circulation, 120, pp. 1640-1645 Wannamethee, S.G., Lowe, G.D., Shaper, A.G., Rumley, A., Lennon, L., Whincup, P.H., The metabolic syndrome and insulin resistance: Relationship to haemostatic and inflammatory markers in older non-diabetic men (2005) Atherosclerosis, 181, pp. 101-108 Ford, E.S., Abbasi, F., Reaven, G.M., Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose (2005) Atherosclerosis, 181, pp. 143-148 Rosenbaum, P., Gimeno, S.G., Sanudo, A., Franco, L.J., Ferreira, S.R., Analysis of criteria for metabolic syndrome in a population-based study of Japanese-Brazilians (2005) Diabetes Obes Metab, 7, pp. 352-359 Aguilar-Salinas, C.A., Rojas, R., Gomez-Perez, F.J., The metabolic syndrome: A concept hard to define (2005) Arch Med Res, 36, pp. 223-231 Rodriguez, A., Muller, D.C., Engelhardt, M., Andres, R., Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore Longitudinal Study of Aging (2005) Metabolism, 54, pp. 542-547 Ishizaka, N., Ishizaka, Y., Toda, E., Hashimoto, H., Nagai, R., Yamakado, M., Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals (2005) Hypertens Res, 28, pp. 27-34 Bo, S., Gentile, L., Ciccone, G., The metabolic syndrome and high C-reactive protein: Prevalence and differences by sex in a southern-European population-based cohort (2005) Diabetes Metab Res Rev, 21, pp. 515-524 Chung, C.P., Avalos, I., Oeser, A., High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors (2006) Ann Rheum Dis, 66, pp. 208-214 Azevedo, G.D., Gadelha, R.G., Vilar, M.J., Metabolic syndrome in systemic lupus erythematosus: Lower prevalence in Brazil than in the USA (2007) Ann Rheum Dis, 66, p. 1542 Sabio, J., Zamora-Pasadas, M., Jiménez-Jáimezmez, J., Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain (2008) Lupus, 17, pp. 849-859 Pereira, R.M., De Carvalho, J.F., Bonfá, E., Metabolic syndrome in rheumatological diseases (2009) Autoimmun Rev, 8, pp. 415-419 Petri, M., Lakatta, C., Magder, L., Goldman, D., Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis (1994) Am J Med, 96, pp. 254-259 Takemoto, M., Liao, J.K., Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (2001) Arterioscler Thromb Vasc Biol, 21, pp. 1712-1719 Crisby, M., Nordin-Fredriksson, G., Shah, P.K., Yano, J., Zhu, J., Nilsson, J., Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization (2001) Circulation, 103, pp. 926-933